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1. Introduction 
1.1 Venous thromboembolism in neonates 
Among children, the group of critically ill newborns presents the largest of population that 
suffering from thromboembolism. Making decisions regarding therapeutic strategies a 
challenge for the intensive care physician as the clinical significance of neonatal   thrombosis 
varies from asymptomatic incidents to life or limb threatening events and, moreover, 
appropriate evidence-based treatment algorithms are lacking. 
This review focuses on the incidence, pathophysiology, risks factors, diagnosis and 
treatment of venous thromboembolism in neonates 
1.2 Incidence 
The incidence of thromboembolic events in the pediatric age group is highest in neonates 
and infants <1 year of age (Monagle et al., 2008). Much of the published data regarding the 
epidemiology of neonatal venous thromboembolism (VTE) has come from national registry 
studies. The Canadian registry (Schmid & Andrew, 1995) reported 97 cases of wich 64 (66%) 
had venous involvement. The German neonatal registry (Nowak-Gottl et al., 1997) reported 
79 cases of symptomatic thrombosis, including stroke. VTE accounted for 76% of cases. The 
overall incidence of symptomatic events was 0.51 per 10,000 births. 
Male and female infants are affected with equal frecuency with the exception of renal vein 
thrombosis, which has a male predominance for unclear reasons (Chalmers, 2006). 
1.3 Pathophysiologic 
We must consider the multiple additive factors that contribute to the development of 
thromboembolism in neonates. Also, the hemostatic system of neonates is significantly 
different from that of children and adults (Veldman, 2008). 
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On the pro-coagulant side, especially the vitamin K-dependent coagulation factors (II, VII, 
IX, and X) and the components of the contact system (FIX,FXII, prekallkreine and high 
molecular weight kininogen) show significantly reduced  plasma activities in neonates 
compared  to children and adults. However, the vitamin K-dependent inhibitors of 
coagulation, protein C and protein S, are also reduced, counterbalancing the reduced 
clotting potential of neonatal plasma. In fact, both antithrombin and protein C 
concentrantions are decreased to approximately 30% of adults values in term and even 
lower in preterm newborns. Neonatal platelets have been reported to be hypo-reactive; 
however, this deficiency seems to be balanced by increased von Willebrand factor activity, 
resulting in overall normal platelet function (Veldman, 2008). 
The activity of the fibrinolityc system in the newborn is reduced compared to adults and 
older children due to both decreased plasma activity of plasminogen and increased plasma 
levels of plasminogen activator inhibitor (PAI). The latter fact may explain the high rate of 
thromboembolic event (TE) associated with intravascular devices in newborns. However, to 
date there is no evidence that the neonatal hemostatic system either protects from or 
promotes thrombus formation. Of course, additional risk factors, eg, critical illness or 
congenital thrombophilia, have to be considered separately from the immaturity of neonatal 
hemostasis (Veldman, 2008). Given the siginificant differences between the plasma factor 
concentrations in different age groups, a detailed knowledge on the development of 
hemostasis is critical for the intensivist in order to adapt pharmacological approaches and 
interpret results from laboratory tests in the neonate with TE (Ignjatovich et al,. 2006; 
Ignjatovich et al,. 2007). 
1.4 Risk factors 
Neonatal VTE is frecuently associated with presence of significant underlying risk factors. 
As in older children central venous lines (CVLs) are the single most important contributing 
factor. Excluding cases of renal vein thrombosis (RVT), CVLs-related thrombosis accounted 
for 89% and 94% of VTE in the Canadian and Dutch registries, respectively (Schmidt and 
Andrew, 1995; van Ommen et al., 2001). These events involve the large vessels most 
frequently used for catheterization including the umbilical vein. Neonatal VTE related to the 
use of the umbilical venous catheter (UVC) has been the subject of studies involving 
sequential imaging. Using venography, Roy et al.,1997 documented UVC-associated 
thrombosis in 14 of 48 neonates (29%). As in older children, many of these events were 
asymptomatic and the incidence of thrombosis was highly dependent on the imaging 
modality used (Chalmers, 2006). 
Critical illness is a well-recognized risk factor for TE in all age groups. Inmobilization, rapid 
changes in intravascular volume and extensive intravascular instrumentation contribute to 
the enhanced risk of venous and arterial thrombosis in patients in intensive care units.  
(Veldman, 2008). Additional risk factors include, but are not limited to, asphyxia, maternal 
diabetes, poor cardiac output and dehydration. Neonates are born with a high hematocrit 
and tend to contract their intravascular volume within the first days of life, making them 
even more prone to thromboembolic events (Veldman, 2008). 
In the neonatal population, sepsis is particularly devastating, as it causes 45% of late deaths 
in the neonatal intensive care unit (NICU). Neonates with sepsis develop an acquired pro-
thrombotic state due to increased consumption of already limited supplies of coagulation 
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inhibitors. Furthermore, plasma activity of plasminogen activator inhibitor (PAI) is 
increased in sepsis and levels of protein C are reduced. The latter fact has been reported to 
correlate with poor outcomes in adults and neonates. Ongoing consumption of coagulation 
factors and platelets resulting in microcirculatory thrombosis likely contributes to sepsis-
induced multi-organ failure and death. Macro-circulatory thrombotic events are rare in this 
setting but can occur, especially in babies who have arterial umbilical catheters (UACs) or 
UVCs in situ (Veldman, 2008). 
Turebylu., 2007 reported that congenital thrombophilia not to be associated with UVC 
thrombosis. Revel-Vilk et al., 2003 reported that in neonates inherited prothrombotic 
coagulation proteins do not contribute significantly to the pathogenesis of venous TEs; they 
concluded that the most siginificant aetiological risk factors are the presence of a central 
venous line and other medical conditions. 
Heller et al., 2000 reported an elevated odds ratio for the presence of congenital 
thrombophilia in neonates with renal, portal or hepatic venous thrombosis and 
recommended that neonates with TE  should undergo an extensive screening, included 
resistance to activated protein C ( APC-R), protein C,  protein S, antithrombin activity, 
activities of coagulation factors VIIIC and XII, lipoprotein-A, histidine-rich glycoprotein, 
heparin cofactor II, antiphospholipid antibodies, lupus anticoagulants, as well as fasting 
homocysteine concentrations. In addition, DNA-based assays (factor V G1691A mutation or 
factor V Leiden, factor II G20210A variant and MTHFR C677T genotype) should be 
considered. Whereas DNA-based mutation analysis can be performed at any time point, 
protein-based assays should not be carried out in the first 6-8 months after the event and 
oral anticoagulation is recommended to be discontinued at 14-30 days before plasma 
samples for thrombophilia diagnosis are drawn.  
Deficiency of one of the important hemostasis control proteins, protein C, protein S or 
antithrombin, occurs less frequently, but results in a more potent prothrombotic state. 
Heterozygous deficiency of these proteins is difficult to diagnose in the newborn period, 
because the neonatal levels are much lower than the adult reference range. Homozygous 
deficiency of Protein C or S typically presents in the perinatal period with significant 
thrombosis resulting in purpura fulminans. Compoud heterozygosity of one of the natural 
anticoagulants in association with Factor V Leiden may cause a similar clinical picture 
(Beardsley, 2007). 
1.5 Diagnosis 
1.5.1 Clinical 
Intravascular catheters are responsible for more than 80% of venous thrombotic 
complications.Signs and symptoms of catheter-related thrombosis vary from diminished blood 
flow through the cateter to tenderness and swelling of the affected extremity or swelling of the 
neck and head associated with superior vena cava syndrome. Although clinically apparent 
thrombi occur in less than 5% of neonates with a central line. (Beardsley, 2007). 
Renal vein thrombosis (RVT) is the most common form of non-catheter-related thrombosis 
(Nathan et al., 2003). Risk factors for RVT include maternal diabetes, dehydration, infection, 
asphyxia, polycythemia, prematurity,critical illness, femoral CVL and male gender 
(chest,913,veldman).  Approximately 80% present within the first month and usually within 
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the first week of life and it is likely that a number of these :events initially  develop 
antenatally. (Monagle et al., 2008; Veldman, 2008). Presenting symptoms and clinical 
findings are different in neonates and older patients and are influenced by the extent and 
rapidity of thrombus formation. Neonates usually have a flank mass, hematuria, 
proteinuria, thrombocytopenia and nonfunction of the involved kidney. (Nathan et al., 
2003). Approximately 25% of cases are bilateral and 52-60% are reported to have evidence of 
extension into the inferior vena caval (IVC). (Monagle et al., 2008). Overall survival 
following neonatal RVT is generally favorable. Four small cohort studies with variable 
follow-up reported 81-100% of neonates survived. Clinical sequelae included chronic renal 
impairment and hypertension. (Monagle et al., 2008) 
Thombosis of the inferior vena cava can present with signs resembling obstruction of the 
renal vein (hematuria and retroperitoneal mass); however, these will occur bilaterally when 
the inferior vena cava is affected. In addition, the lower limbs may be edematous and, if 
blood flow is susbstantially impared, the child may be in respiratory distress and may have 
high blood pressure. (Veldman, 2008) 
Signs of impared liver function, hepatomegaly and splenomegaly should raise the suspicion 
of portal vein thrombosis (PVT); however, only about 10% of children with PVT develop 
acute clinical symptoms (Veldman, 2008). 
1.5.2 Imaging 
The echocardiography or abdominal ultrasound is the most commonly applied diagnostic 
method to confirm clinical suspicion of TE or to screen babies for clinically silent disease. 
(Roy et al, 2002) comparing echocardiographic investigations with venograms and reported 
a sensitivity of 21-43% and specificities ranging from 76-94%. This study concluded that 
venography is required to accurately diagnose UVC related TE in neonates. 
1.5.3 Laboratory 
Initial laboratory  work-up in a neonate in whom thrombosis is suspected should include a 
full blood count as well as a coagulation screening with determination of prothrombin time, 
thrombin time and activated partial thromboplastin time. 
D-dimers are a positive finding in almost all critically ill neonates. Conversely, negative D-
dimers are relatively accurate in ruling out thrombosis in most patients, including neonates.  
In almost all neonates, platelet numbers decrease after birth. However, a sudden and severe 
drop in platelet counts should alert the intensivist. The thrombocytopenia remains one of 
the most sensistive indicators for micro- (in the setting of sepsis) or macro-circulatory 
thrombosis (Veldman, 2008). 
Also it has been recommended that infants who are diagnosed with clinically significant VTE 
should undergo testing for inherited and acquired thrombophilic traits. (Beardsley, 2007). 
1.6 Management 
There are no published randomized controlled trials (RCTs) and no large cohort studies that 
report on the outcomes of different treatment modalities in the management of neonatal 
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VTE. Valuable and comprehensive evidence-based clinical practice guidelines have been 
developed by the American College of Chest Physicians (ACCP) on antithrombotic therapy 
in neonates and children (Monagle et al, 2008). Their recommendations are necessarily 
based on extrapolation of principles of therapy from adult guidelines, limited clinical 
information from registries, individual case studies and knowledge of current common 
clinical practice.  
The following is the summary of the recommendations of the ACCP 2008 on 
Anticoagulation and Trombolytic Therapy for neonates with VTE: We suggest that central 
venous lines (CVL) or UVCs associated with confirmed thrombosis be removed, if possible, 
after 3 to 5 days of anticoagulation (Grade 2C).It is a weak recommendation. We suggest 
either initial anticoagulation, or supportive care with radiologic monitoring (Grade 2C); 
however, we recommend subsequent anticoagulation if extension of the thrombosis occurs 
during supportive care (Grade 1B). It is a strong recommendation.  We suggest 
anticoagulation should be with either of the following: (1) LMWH given bid and adjusted to 
achieve an anti-FXa level of  0.5–1.0 U/mL: or (2) UFH for 3 to 5 days adjusted to achieve an 
anti-FXa of 0.35 to 0.7 U/mL or a corresponding APTT range, followed by LMWH. We 
suggest a total duration of anticoagulation of between 6 weeks and 3 months (Grade 2C).  
We suggest that if either a CVL or a UVC is still in place on completion of therapeutic 
anticoagulation, a prophylactic dose of LMWH be given to prevent recurrent VTE until such 
time as the CVL or UVC is removed (Grade 2C).  We recommend against thrombolytic 
therapy for neonatal VTE unless major vessel occlusion is causing critical compromise of 
organs or limbs (Grade 1B). We suggest that if thrombolysis is required the clinician use tPA 
and supplement with plasminogen fresh frozen plasma) prior to commencing therapy 
(Grade 2C). For neonates or children with unilateral renal vein thrombosis (RVT) in the 
absence of renal impairment or extension into the inferior vena cava, we suggest supportive 
care with monitoring of the RVT for extension or anticoagulation with UFH/LMWH or 
LMWH in therapeutic doses; we suggest continuation for 3 months (Grade 2C).  For 
unilateral RVT that extends into the inferior vena cava, we suggest anticoagulation with 
UFH/LMWH or LMWH for 3 months (Grade 2C). For bilateral RVT with various degrees of 
renal failure, we suggest anticoagulation with UFH and initial thrombolytic therapy with 
TPA, followed by anticoagulation with UFH/LMWH (Grade 2C).Remark: LMWH therapy 
requires careful monitoring in the presence of significant renal impairment. 
2. Venous thromboembolism and chronic kidney disease 
Pulmonary embolism and Deep Vein Thrombosis are a wide spectrum of a single disease 
defined as Venous Thromboembolism, and it occurs for the first time in approximately 100 
persons per 100,000 each year in the United States and rises exponentially from less than 5 
cases per 100,000 persons at 15 years and less to approximately 500 cases per 100,000 
persons at age 80 years (White, 2003; Ageno, 2006; Heit, 2008). 
An understanding of the risk factors for venous thrombosis is necessary in order to increase 
the prevention of this disease in high risk individuals and groups of patients. 
The major risk factors for thrombosis include endogenous pattern characteristics like obesity 
and genetic factors, and triggering factors such as surgery, immobility or pregnancy. Venous 
thrombosis tends to occur due to additive effects of endogenous, genetic and environmental 
risk factors present simultaneously (Cushman, 2007). 
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Chronic kidney disease is common in the general population, affecting   13% of adults in the 
United States between   1999 and 2004 (Coresh 2007). 
There are several questions about the relation between   venous thromboembolism and 
chronic kidney disease.  Is the chronic kidney disease a risk factor for venous 
thromboembolism?  What are the mechanisms involved in these diseases? And finally how 
to treat these patients? 
2.1 Epidemiology of thromboembolism associated to chronic kidney disease 
2.1.1 Chronic kidney disease and venous thromboembolism 
There are few prospective studies about this association, with this objective and using the 
data from the Longitudinal Investigation of Thromboembolism Etiology Study, 19,073 
middle-aged and elderly adults were categorized on the basis of the determination of the 
glomerular flltration rate and cystatin C (data avalaible in 4,734 participants). During a 
mean follow up time of 11.8 years, 413 participants developed venous thromboembolism (41 
% idiopathic and 59% secondary). Compared with the participants with normal kidney 
function, the relative risk for venous thromboembolism was 1.28 (95% confidence interval) 
for those with mildly decrease kidney function and 2.09 for those with stage 3 or 4 of chronic 
kidney disease. The authors concluded that middle –age and elderly patients with chronic 
kidney disease stages 3 through 4 evidence all increased risk for incident venous 
thromboembolism, suggesting that prophylaxis may be particularly important in this 
population (Wattanakit, 2008). 
Similar results were reported by Folsom et al, in a prospective cohort of 10,700 patients, in 
whom estimated the glomerular filtration rate  from prediction equations based on serum 
creatinine or cystatin  C, and follow up for the occurrence of venous thromboembolism for 
over a median of 8.3 years. The adjusted hazard ratios of total venous thromboembolism 
and estimated glomerular filtration rate based in cystatin C was 1.0 for normal kidney 
function, 1.4 for mildly impaired renal function   and 1.94 for stage 3 and 4 of chronic kidney 
disease, these hazard ratios were moderately attenuated to 1.0, 1.26 and 1.6 respectively 
with adjustment for hormone replacement therapy, diabetes and body mass index. 
Association between chronic kidney disease, based on estimated glomerular filtration rate 
using cystatin C, and venous thromboembolism were slightly stronger for idiopathic venous 
thromboembolism than for secondary venous thromboembolism. In contrast, creatinine  
glomerular filtration rate was no associate with total venous thromboembolism 
occurrence.(Foslom, 2010). 
Another prospective cohort study 8,495 subjects whit chronic kidney disease stages 1 to 3 in 
which renal function and albuminuria were assessed, they concluded that stages 1 or 2 of 
chronic kidney disease are risk factors for venous thromboembolism in presence of 
albuminuria, and the risk of venous thromboemboslim is more related to albuminuria than 
to impaired glomerular filtration rate (Ocak 2010).  
2.1.2 End-stage renal disease and venous thromboembolism 
Independent of co-morbidity chronic dialysis patients have high risk for pulmonary 
embolism, in 1996 in the United States, the overall incidence rate of pulmonary embolism  
www.intechopen.com
Venous Thromboembolism in Neonates, Children and  
Patients with Chronic Renal Disease – Special Considerations 43 
was 149.9/100,000 dialysis patients, compared with 24.6/100,000 persons in the general 
population. In this study the younger dialysis patients had the greatest relative risk for 
pulmonary embolism (Tveit, 2002). Similar results by Allen et al, that showed  an incidence 
of 8.3% of venous thromboembolism in dyalisis patiens  (Allen, 1987).  
2.1.3 Nephrotic syndrome and venous thromboembolism 
Several studies consider Nephrotic Syndrome as a risk factor for venous thromboembolism. 
In one of the largest studies, Kayali el al, studied  925,000 patients discharged from hospitals 
in the United States with the diagnosis of nephrotic  syndrome, 0.5% had  pulmonary 
embolism, 6.5% had deep vein thrombosis and less than  0.5% had renal vein thrombosis. 
The relative risk of pulmonary embolism (in patients with the nephrotic syndrome) was 1.39 
and for deep vein thrombosis was 1.72. Among patients aged 18-39 years the relative risk of 
deep vein thrombosis increases to 6.81 (Kayali, 2008). 
Another prospective study of 298 patients with nephrotic syndrome, with a mean follow up 
of 10±9 years, the annual incidence of venous thromboembolism was 1.02%, over the first 6 
months of follow up; the rate of venous thromboembolism was 9.85. In this group of 
patients, proteinuria and serum albumin levels tended to be related to venous 
tromboembolism, however, only the predictive value of the ratio of proteinuria to serum 
albumin was significant but not the estimated glomerular filtration rate.(Bakhtawar, 2008) 
For instance, estimated glomerular filtration rate using cystatin C, albuminuria and ratio 
proteinuria to serum albumin have predictive value for venous thromboembolism in 
patients with chronic renal disease. 
2.1.4 Renal transplantation and venous thromboembolism 
In renal transplantation, few studies had evaluated the risk of venous thromboembolism,  
the largest one used the United States Renal Data System database to study 28,924 patients  
receiving a kidney transplant, the rate of VTE occurring 1.5 to 3 years after transplantation 
was 2.9 episodes/1,000 person-years. Estimated glomerular filtration rate less than 30 
mL/min/1.73 m2 versus higher at the end of the first year after renal transplantation was 
associated with significantly increased risk for later venous thromboembolism (adjusted 
hazard ratio, 2.05; 95% confidence interval, 1.08 to 3.89).  Patients with severe chronic kidney 
disease, after renal transplantation should be regarded as high risk for late venous 
tromboembolism, which is a potentially preventable cause of death in this population 
(Abbott, 2004). 
A prospective study of a cohort of 578 patients with renal transplantation, reports 9.1 % 
incidence of deep vein thrombosis of the lower limbs, 39.5% were asymptomatic and the 
diagnosis was made during routine ultrasound examination. Those patients, who 
experience venous thromboembolism, were at high risk of recurrence after 
thromboprophylaxis withdrawal (Poli, 2006).  
Co-morbilities like diabetes mellitus could increase the risk of venous thromboembolism, in  
a prospective study the frequency of deep vein thrombosis during the first 3 
weeks after kidney transplantation has been evaluated using the combination of 
thermography and strain-gauge plethysmography for objective diagnosis. 83 consecutive 
www.intechopen.com
Pathophysiology and Clinical Aspects of  
Venous Thromboembolism in Neonates, Renal Disease and Cancer Patients  44
patients were included, 33 with juvenile diabetes mellitus. The overall frequency 
of thrombosis was 24.1%, diabetes mellitus being a significant risk factor (Bergqvist, 1985). 
Epidemiological studies have attempted to define risk in terms of modifiable (drugs, 
dialysis modality, surgical procedure) and no modifiable (age, diabetes mellitus, vascular 
anomalies, factor or identify changes in coagulation or fibrinolysis) promoting a more 
thrombotic state. Most recently the evolution of thrombophilia research has established the 
potential for inherited hypercoagulability to predispose to acute allograft thrombosis. 
Inheritance of the factor V Leiden (FVL), prothrombin G20210A mutation, or the presence of 
antiphospholipid antibodies may increase the risk of renal allograft thrombosis certain 3-
fold in selected patients. Patients with end-stage renal disease due to systemic lupus 
erythematosus appear at particularly high risk of thrombosis, especially if they have either 
antiphospholipid antibodies or detectable β2-glycoprotein-1. (Irish, 2004). 
2.2 Mechanisms of venous thrombosis in patients with chronic kidney disease 
The individual risk of venous thromboembolism varies as a result of a complex interaction 
between congenital and transient or permanent acquired risk factors. 
Virchow summarized the pathophysiology of venous thromboembolism in his famous triad: 
venous stasis, endothelial damage and hypercoagulability (Ageno 2006 as cited in Virchow, 
1856) 
Stasis predisposes to venous thrombosis by reducing the clearance of activated coagulation 
factors, the mixing of this activated coagulation factors and inhibitors and the dilution of 
activated coagulation factors. 
Vessel wall damage is more important in the pathogenesis of arterial thrombus. Venous 
endothelial damage results in endothelial cell detachment and exposure of blood to tissue 
factor and other subendothelial components that activate coagulation. 
Hypercoagulable states could be in several situations: increase thrombin production 
following surgery or decrease activity of endogenous anticoagulants. 
On the whole, venous thromboembolism probably has understood as a multicausal disease 
in which more than one genetic or environmental condition  coincides to produce clinically 
apparent  thrombosis (Rosendaal,1999). 
2.2.1 Procoagulant markers 
To elucidate the mechanisms that could increase the risk of venous thromboembolism in 
patients with chronic kidney diseases, some studies had investigated the levels of the 
procoagulant markers. 
Patients with end stage renal disease and predialysis renal failures, nephrotic syndrome and 
mildly chronic kidney disease had elevated level of C Reactive Protein, fibrinogen, d-dimer, 
Factor VIII, Factor VII, and Von Willebrand, these high levels are due to increase synthesis 
out of proportion to urinary loss while lower levels of coagulation factors like IX, XI, and XII 
due to increased urinary loss (Keller, 2008; Vaziri, 1980). On the other hand, an association 
between increased levels of coagulation factors VIII, FIX and F XI and an increased risk of 
venous thromboembolism has been reported, the mechanisms and clinical significance of 
such association are still unclear (Crowther, 2003). 
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2.2.2 Decrease endogenous anticoagulants 
In the nephrotic syndrome  the hypercoagulable state is distinguished by an increase in 
coagulation factors (V, VIII and fibrinogen) a decrease in the levels of antitrombin III and S 
Proteins, an increase  in alpha 2 antiplasmin activity and exaggerated platelet adhesiveness  
and aggregation. This prothrombotic state may be aggravated by additional rheological 
factors (immobilization, diuretic therapy, etc.) (Keusch, 1989; Adams, 2008). 
The lower level of antithrombin III in patients with nephrotic syndrome is probably due to 
increased urinary loss.(Vaziri, 1984). 
2.2.3 Platelet activation and aggregation 
P-selectin is a marker of platelet activation and is increased in nephrotic syndrome patients. 
Platelet aggregation increases because of hypoalbuminemia   that result in an increase 
avalaibility of thromboxane a-2 that is a potent platelet agonist (Jackson, 1982). 
2.2.4 Reduced fibrinolysis  
Fibrin cloths with reduced permeability, increased clot stiffness and reduced fibrinolysis 
susceptibility may predispose to thrombosis. Using permeability and turbidity studies in 22 
end stage renal disease patients and 24 healthy controls. Fibrin clots made from plasma of 
patients with chronic renal disease were found to be less permeable, less compactable and   
less susceptible to fibrinolysis than clots from controls (Siǿland, 2007).  
Another study  in 33 patiens  in long term haemodialysis  has demonstrated  unfavorably 
altered clot properties  that may be associated with increase cardiovascular  mortality 
(Unaas, 2008) There are studies that demonstrates  that individuals  with reduced 
fibrinolytic potential as measured by plasma based assays , have an increased risk of 
developing a first venous thrombosis. Whether this hypofibrinolytic state determined by 
genetic or adquired factors or a combination of them and which proteins are evolved is at 
present unknow (Lisman, 2005). 
In conclusion, chronic kidney disease  patients presents  a pro-thrombotic state that 
increases the risk of venous thromboembolism  and comprises alteration of platelet 
functions, coagulation factors, endogenous  anticoagulants  and fibrinolytic system,  many 
mechanism are still unknown and opens a potential  field for investigation. 
2.3 Treatment of venous thromboembolism in chronic renal disease patients 
Anticoagulants are widely used to prevent and treat venous thromboembolism, these drugs 
are often used in patients with renal impairment. Renal impairment is at the same time, a 
risk factor for bleeding and thrombosis during anticoagulant therapy and may influence the 
balance between the safety and efficacy of such drugs (Harder, 2011). 
The available anticoagulants for the treatment of thromboembolism are heparins, the Factor 
X inhibitor fondaparinux, warfarin and the new anticoagulants Factor X inhibitors and 
direct thrombin inhibitors. Most of the antithrombotics are eliminated primarily by the 
kidneys , so dosing in patients with several renal impairment  may require dosage reduction  
or increase frequency of monitoring  for bleeding and  thromboembolism complications or 
both(Lobo, 2007). 
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Decisions for anticoagulation therapy respect the agent selected, dose, duration of 
treatment, and approaches to monitoring should balance the risks between bleeding and 
thrombosis. 
2.3.1 Indirect thrombin Inhibitors 
2.3.1.1 Unfractionated Heparin (UFH) 
Heparin is a large, heterogeneous compound of approximately 45 saccharide units that 
indirectly binds to and increases the enzymatic activity of antithrombin III, against activated 
Factors II, and X. Unfractionated Heparin clearance is the result of a combination of rapid, 
saturable mechanism via the endothelium and the reticuloendothelial system in liver, and a 
slower, non saturable mechanism through the kidneys (Follea, 1987)  However UFH remain 
the anticoagulant choice for in-hospital treatment of patients with thromboembolic  
disorders who also have renal dysfunction. 
There are no recommendations from the American College of Chest Physicians (ACCP) 
Consensus Conference on Antithrombotic Therapy and from the manufacturers for dose 
reduction of UFH in patients with chronic renal impairment (Kearon, 2008). The monitoring 
of the activated  partial thromboplastin time is recommended while UFH are administered 
to  renal impairment patients. 
In acute thromboembolic events, an intravenous bolus dose up to 80 units/kg may be 
administered, but in the absence of an emergent need for anticoagulation or high risk 
situations, the bolus dose could be omitted and just a continuous infusion may be initiated 
with the advantage of gradually establishing of the anticoagulation and limiting the risk of 
bleeding. Initial continuous infusion of unfractionated heparin do not require special 
adjustments because of chronic kidney disease alone and goal activated partial time of 
thromboplastin should be targeted to the indication for anticoagulant therapy. Another 
option is  subcutaneous  weight adjusted dosing. (Dager, 2010) 
2.3.1.2 Low molecular weight heparin (LMWH) 
Low molecular weight heparins may not be considered as the preferred option for initial 
parenteral anticoagulation in chronic kidney disease patients, but they could be considered 
in special situations because these agents are primarily eliminated on kidneys and dosing 
adjustments are needed as renal failure progresses (Kearon, 2006). 
A meta analysis was performed to study the incidence of  bleeding  in chronic kidney 
disease patients treated with low molecular weight heparins like enoxaparin, dalteparin and 
tinzaparin. Enoxaparin has elevated levels of anti-factor Xa and an increased risk for mayor 
bleeding, suggesting empirical dose adjustment of enoxaparin in patients with severe renal 
impairment. In patients with mild to moderate renal impairment there are not required dose 
adjustment of enoxaparin  [ Lim, 2006 ] 
For venous tromboembolism prophylactic doses of enoxaparin the American College of 
Chest Physicians (ACCP) recommendations for patients with severe renal impairment is to 
lower or halve the standard dose. For the treatment of venous thromboembolism  in patients 
with severe renal impairment the ACCP guidelines recommended either using 
unfractionated heparin instead of low molecular weight heparins. No especific dose 
recommendations are made in this guidelines for other low molecular weight heparins in 
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venous thromboembolism. For tinzaparin and dalteparin monitoring of anticoagulant 
activity in patients with renal failure should be considered. 
2.3.1.3 Fondaparinux 
Fondaparinux is a synthetic pentasaccharide, that inhibits factor Xa by binding to  
antithrombin. After subcutaneous administration the peak plasma concentration is achieved 
within 2 hours, the half life is 17 hours in young healthy subjects and 21 hours in the elderly. 
Up to 80% of fondaparinux is eliminated as unchanged drug via the kidneys. 
However the ACCP guidelines  for VTE prevention do not recommend specific doses 
adjustments for fondaparinux in renal impaired patients, depending of the circumstances 
the guidelines recommended  avoiding the anticoagulant, lowering dose or monitoring 
anticoagulant activity      [Hirsh,2008] 
The summary of manufacturers insert states contraindicated of fondaparinux in patients with  
severe renal impairment  (clearance of creatinine ‹20 ml/min) and use  with caution in patients 
with  moderate renal impairment (creatinine clearance 30 a  50 ml/min)[ Harder 2011] 
2.3.2 Vitamin K antagonists 
Vitamin K antagonist inhibit the hepatic synthesis of factors II, VII, IX and X and protein C 
and S. There are various vitamina K antagonists, however, warfarin   is the most commonly 
used around the world. 
After oral administration warfarin is rapidly absorbed reaching the plasma peak 
concentration within 90 minutes, the peak therapeutic effect is acquired at 36 hours. 
Warfarin undergoes oxidative metabolism via the CYP450 system in the liver and less than 
1% of the drug is excreted unchanged in the urine. (Ansell, 2008) 
The risk of bleeding and thromboembolic complications is increased when using warfarin in 
the chronic kidney disease population and depends of the INR target, incidence of values 
outside of the target or other comorbid conditions. Warfarin dosing requirements tend to be 
lower as renal function declines. (Limdi , 2009) Concurrent drug interactions and acute 
medical problems such as heart failure or infections can influence the dose response to 
warfarin. Because  the complexity of managing warfarin  and increased risk of adverse 
outcomes  in the chronic  kidney disease setting, warfarin management in those patients 
should be referred when  possible to dedicated anticoagulant services.(Dager ,2003). 
2.3.3 Novel oral anticoagulants in patiens with renal disease 
2.3.3.1 Dabigatran etexilate 
Dabigatran etexilate is a direct thrombin inhibitor, currently approved for the prevention of 
venous thromboembolism in orthopedic surgery patients. After oral administration peak 
plasma concentrations are achieved within 2 hours of administration. Elimination of 
dabigatran is predominantly via the renal pathway, 80% of the administered dose is 
excreted unchanged in the urine within the first 24 hours after an intravenous dose and is 
contraindicated in patients with severe renal impairment (Stangier, 2008) 
Limited data are avalaible on dabigatran pharmacokinetics in patients with renal 
impairment for venous thromboembolism treatment.(Dahl, 2009) 
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2.3.3.2 Rivaroxaban 
Rivaroxaban  inhibits both free and clot-bound Factor Xa, this oral anticoagulant has been 
approved for the prevention of venous thromboembolism after elective hip or knee 
replacement surgery in adults (Bauer, 2008) 
Rivaroxaban has a dual mode of elimination hepatic and renal and the inhibition of factor 
Xa activityalso increased with the reduce renal function. Rivaroxaban is not recommended 
for patients with a Creatine clearance of less than 15 mil/min. (Kubitza, 2010). To the date 
there are not reported studies for rivaroxaban in patients with renal impairment for venous 
thromboembolism. 
2.3.3.3 Apixaban  
Apixaban inhibits both free and clot-bound factor Xa Apixaban is rapidly absorved in the 
stomach and small intestine, reaching peaks concentrations approximately 1 to 3 hours after 
oral administration. The elimination includes renal and biliary excretion, and the drug has a 
mean elimination  half life of 8 to 15 hours. ( Shantsila, 2008;Frost,2007) 
There are limited data about the clearance of apixaban in patients with renal impairment. 
In presence of heparin induced thrombocytopenia or antithrombin deficiency directs 
thrombin inhibitors may be options for anticoagulation. They are argatroban, bivalidurin 
and lepirudin, avalaible only by continous venous infusion or subcutaneous injection. 
2.3.3.4 Argatroban 
Argatroban is eliminated in liver and no adjustment in dosing is required for renal 
insufficiency or hemodyalisis, the mean dose in heparin induced thrombocytopenia was 1.6 
μg/kg/min, targeting activated partial thromboplastin time 1.5 to 3.0 times control. In 
patients with renal failure it has been suggest lower dosing requirements with dose 
reduction of approximately 0.1 to 0.6 μg/kg/min for each 30 ml/min decrease in the 
creatinine clearance. (Hursting, 2008; Arpino, 2004) 
2.3.3.5 Lepirudin 
Lepirudin is the agent most dependent of renal elimination and requires significant dose 
reductions as renal function declines.   
2.3.3.6 Bivalirudin 
Bivalirudin is eliminated independent of renal function, with 80% removed enzimatically, it 
has also been observed to be removed by ultrafiltration. For patients with renal dysfunction 
and heparin induced thrombocytopenia, dose reductions has been suggested. The extend 
depends on the degree of renal dysfunction and form of renal replacement therapy. The 
target activated partial thromboplastin time for both lepirudin and bivalirudin is 1.5 to 2.5 
times baseline and argatroban 1.5 to 3 times baseline, which may be different from the range 
specified for unfractionated heparin.(Dager, 2007; Kiser,2008). 
In conclusion the unfractionated heparin continues been the anticoagulant of choice for 
chronic kidney disease patients, because it’s short half life, reliable monitoring, reversibility 
and independence of renal function. Of the oral anticoagulants, warfarine is a safe 
alternative to unfractionated heparin, easy to monitor and does not requires dose alteration 
in chronic kidney disease. 
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Stage Kidney damage Glomerular filtration rate CrCl, 
mL/min/1.73m2 
1 Normal o Increased GFR ≥90
2 Mild decrease in GFR 60 to 80
3 Moderate decrease in GFR 30 to 59
4 Severe decrease in GFR 15 to 29
5 Kidney failure (End stage renal disease) <15(or dialysis)
CrCl: creatinine clearance 
a Clasification  by National Kidney Foundation. Chronic kidney disease is defined as either 
kidney damage or GFR of <60 mL/min/1.73m2 for ≥ 3 months. Kidney damage  is defined 
as pathological abnormalities or markers of damage, including abnormalities in blood or 
urine test or imaging studies.GFR reported by  the National Kidney Foundation, using 
the modification of Diet in Renal Disease Study equation based on age, gender, race, and 
serum creatinine 
[Reference: Harder, 2011] 
Table 1. Clasification of Renal impairment 
 
Anticoagulant Elimination Half life* Monitoring Antidote Dose 
adjustment in 
severe renal 
impairment 
UFH RES,renal 
minimal 
30-150 min after 
IV administration
aPTT, 
anti Xa 
ACT 
Protamine No dose 
adjustment 
Monitoring 
high doses 
LMWH Mainly renal
RES minimal 
2-8 h after SC 
administration 
Anti Xa Protamine 
partially 
effective
Yes 
Bivalirudin Proteolytic 
cleavage 80% 
Renal 20%
~25 min after IV 
administration 
ACT None Yes 
Argatroban Hepatic 
100%(CYP3A4)
40-50 min after 
IV administration
aPTT,ACT,
ECT
None No 
Fondaparinux Renal>80% 17 -21 h after SC 
administration
Anti Xa None Drug no 
recommended  
Vitamin K 
agonists 
 
Hepatic 100% 
(CYP2C9) 
~36-42 h INR Vitamin K Careful dose 
titration 
Rivaroxaban 
 
Renal 50% 
hepatic 50%
7 -11 h Anti Xa None Not 
recommended 
Dabigatran Renal 80% 8 -10 h ECT None Not 
recommended 
Apixaban Renal 50% 8 – 15 h INR, aPTT,   
Anti Xa
None Yes 
ACT =Activated clotting time; aPTT=activated partial thromboplastin time; CYP= cytochrome p450 
ECT = ecarin clotting time; INR= International normalized ratio; IV =Intravenous; LMWH= low molecular 
weight heparin; RES= reticuloendothelial system; SC= subcutaneous; UFH= unfractionated heparin. 
{Reference: Grand’Maison A, Charest A,Geerts W, 2005 ; Harder S,2011]  
Table 2. Anticoagulants characteristics and dose adjustment in severe renal impairment 
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While low molecular weight heparins, fondaparinux and direct thrombin inhibitors may 
offer alternatives to unfractionated heparin in patients with chronic kidney disease, more 
evidence are needed to determine the safe dose and monitoring strategy. 
3. Thrombosis in infants and children 
Thromboembolism (TE) is still regarded as a rare event in childhood and therefore 
knowledge of diagnostics, therapy and prophylaxis is limited among general pediatricians. 
During the past years, however, it is increasingly recognized as having significant impact on 
mortality, chronic morbidity and the normal development of children, which has led to an 
enhanced sensitivity toward considering such events in respective patients. Besides the 
greater awareness, an objective increase in childhood thrombosis is due to the medical 
progress in the treatment of critically ill patients. This seemingly contradictory observation 
is easily explained by the increasing use of central catheters and innovative interventional 
procedures in the treatment of premature infants, neonates and older children who are 
critically ill, suffering from complex cardiac defects, and from malignant disease, 
respectively. Therapeutic and prophylactic measures have subsequently become 
increasingly important, but in addition to the complexity of the clinical background and the 
heterogeneity in the pattern of acquired and inherited risk factors for TE among patients, the 
physiological significant differences of the coagulation system between newborns, young 
children and adolescents and differences in drug metabolism do not allow general 
recommendations for therapeutic interventions like thrombolysis and prophylactic 
anticoagulation for the different clinical conditions. This situation is further complicated by 
a lack of availability of pediatric formulations and pediatric data for new drugs.  
The increasing knowledge of exogenous and endogenous thrombophilic risk factors has 
initiated a number of studies to assess the impact of such factors with respect to their 
contribution to the thrombophilic state, both individually but also in concert with other 
factors. In addition to their impact on a first thrombotic event, much of the interest is now 
focused on their importance for thrombotic relapses. Only such studies will give us an 
answer to questions concerning the indications for treatment, prophylaxis and its optimal 
duration. All management recommendations are reflecting the authors’ experiences and 
opinions and are not based on evidence gained by controlled trials as such trials are either 
completely lacking or still ongoing.  
3.1 Epidemiology  
The annual incidence of TE in childhood in general is considerably lower than in adults, 
with a reported frequency of 0.07 to 0.14 per 10.000 children or 5.3 per 10,000 referrals of 
children to the hospital. The results of a prospective German study suggested an incidence 
of 5.2 per 100,000 neonates, and a prospective Dutch study resulted in an estimate of 1.4 per 
100,000 children and adolescents (Parasuraman & Goldhaber , 2006). More than 80% of TE in 
childhood were on a background of a severe preceding illness or other comparable 
predisposing factors. (Kuhle et al, 2004) Arterial TE in children is less common than venous 
thrombosis (Kuhle et al, 2004) with the exception of stroke. The estimated yearly incidence 
of stroke in childhood is between 3–8 per 100,000. (Giroud et al, 1995; Lynch et al, 2002). The 
highest incidence of 25–35 per 100,000 live births has been reported for neonates (Chalmer, 
2005). In addition to its impact on the development of children, stroke also quantitatively 
plays the most important role.  
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The reasons for the lower incidences of TE in children compared to adults are not 
completely understood; an intact vascular endothelium, the lower capacity of thrombin 
generation (Haidi et al, 2006) and elevated levels of -2-macroglobulin, an inhibitor of 
thrombin, are possible age-dependent modifying factors in children. There are two age-
related peaks in the frequency of thromboembolic disorders in children and adolescents: the 
first peak corresponds to the perinatal/neonatal period, with the highest relative incidence, 
and the second is observed post puberty in adolescents, with a higher frequency in 
females.(Kuhle et al, 2004; Stein et al, 2004).  
The relatively higher incidence in neonates as compared to older children may be due to 
higher hematocrit, and the greater lability of the hemostatic system in neonates due to the 
generally decreased levels of both coagulation factors and their inhibitors in this age group, 
except factor VIII (FVIII) and von Willebrand factor (VWF) which are normal or even 
elevated.(Monagle et al, 2006) In adolescents the incidence equals that of young adults, 
probably due to the hormonal status, the use of contraceptives or pregnancy in young 
women, obesity and smoking.(Stein et al, 2004).  
Clearly, these epidemiological data have to be considered when assessing the individual 
absolute thrombotic risk of children with thrombophilia.  
3.2 Diagnosis  
3.2.1 Clinical presentation 
Pain, swelling and discoloration of extremities are acute symptoms of deep vein thrombosis 
(DVT). Vena cava inferior thrombosis manifests with prominent cutaneous veins and possibly 
liver or renal dysfunction depending on the site and extension of the thrombus. Superior vena 
cava thrombosis leads to cyanosis and swelling of the head and upper thorax with prominent 
collateral veins and may finally result in acute cardiac failure. Portal vein thrombosis, in most 
cases due to central catheters, and renal vein thrombosis with hematuria as a frequent sign 
may result in functional impairment or even failure of liver and renal function, respectively. 
Acute chest pain and dyspnea could suggest pulmonary embolism. Acute headache, visual 
impairment, cerebral convulsions and signs of venous congestion may indicate sinus venous 
thrombosis. Signs and symptoms of central venous catheter (CVC)-associated DVT are loss of 
CVC patency, the need for local thrombolytic therapy or CVC replacement, CVC-related 
sepsis, or prominent collateral circulation over chest, neck and head.  
Childhood arterial ischemic stroke (AIS) manifests in neonates preferentially with seizures and 
abnormalities of muscle tone, whereas in elder children hemiparesis is the most frequent 
neurologic sign.(Steinlin et al, 2005) Acquired or inherited severe deficiencies of protein S and 
protein C are disorders involving both the microcirculation and arterial vessels and may 
manifest with characteristic symptoms such as deep skin necrosis (purpura fulminans), 
blindness due to retinal vessel occlusion and arterial embolism followed by necrosis of distal 
extremities or whole limbs. Thrombotic thrombocytopenic purpura (TTP), a severe 
microangiopathic disorder is characterized by nonimmunologic hemolytic anemia and 
thrombocytopenia, neurologic symptoms, and renal, pulmonary and cardial involvement.  
3.2.2 Laboratory parameters 
Every thrombotic event initiates a particular response to re-establish the balance of the 
hemostatic system, e.g., by fibrinolysis. Subsequently markers of fibrinolysis such as D-
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dimers can be detected in the circulation. The specificity of these markers is low; however, 
the negative predictive value of the D-dimer test to correctly exclude DVT is as high as 89% 
in adult patients with likely DVT compared to 99% in patients who were categorized as 
unlikely to have DVT.(Wells et al, 2003) In a study on the outcome of TE in children, 
elevated D-dimer and/or FVIII:C were found in only 67% of the patients; however, elevation 
of these markers at diagnosis and during follow-up are significantly correlated with 
persistence or recurrence of TE and/or a post-thrombotic syndrome. (Goldenberg et al, 2004)  
3.2.3 Imaging 
Color Doppler ultrasound, conventional and MRI angiography, lineograms and 
echocardiography are the diagnostic means of imaging the occlusion of vessels. Pulmonary 
embolism of proximal pulmonary arteries can be visualized by echocardiography and by CT 
scan; however, the specificity and sensitivity are low in detecting more distal clots. In such 
cases ventilation and perfusion scintigraphies are the recommended techniques for 
children.(Babyn et al, 2005) Transcranial Doppler ultrasound is used to assess the risk of stroke 
in patients with sickle cell disease. All techniques can be regarded as equally specific, sensitive 
and precise; their application, however, differs with respect to the region of interest, age and 
therapeutic options. Table 3 lists the different techniques with respect to their application.  
 
Method Indication Limitations
Lineograms CVC related thrombosis Only clots at the tip of the CVC and the 
distal adjacent vessel wall
Color Doppler 
ultrasound 
DVT, SVT* Exception: subclavian vein, use 
venography
Bilateral venography DVT, SVT Exception: jugular vein, use color 
Doppler ultrasound conventional or MRI 
Echocardiography CVC-related thrombosis, 
intracardial thrombus, 
pulmonary embolism
Distal clots in PE
Scintigraphy Pulmonary embolism —
Abbreviations: CVC, central venous catheter, DVT, deep vein thrombosis, SVT, Sinus venous 
thrombosis 
* in young infants through the patent fontanella.
Table 3. Imaging methods for Thromboembolism in neonates and children. 
3.3 Prothrombotic risk factors  
Assessment of prothrombotic risk factors is by no means suitable for diagnosing TE. It may 
possibly help to explain unusual manifestations of TE; however, the predictive power 
concerning outcome, thereby providing a basis for therapeutic and prophylactic decisions is 
still a matter of ongoing studies and debate. Interpretation of laboratory data is strongly age 
dependent since normal ranges may differ considerably between newborns, young children 
and adolescents.  
3.3.1 Hereditary prothrombotic factors 
The most important factors involved in the genetic predisposition to thrombophilia are the 
factors of the coagulation cascade and in particular their natural inhibitors. It is not clear if 
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genetic defects of fibrinolysis also contribute to the hypercoagulable state. Certain metabolic 
defects also cause thrombophilia.  
3.3.1.1 Coagulation factors 
3.3.1.1.1 Fibrinogen (FI) 
In addition to being the final substrate for thrombin, FI is also an acute-phase protein that 
may lead to acquired thrombophilia and may also contribute to the risk of arterial 
TE.(Rothwel et al, 2004) Genetic defects causing dysfibrinogenemia associated with 
thrombophilia are rare.  
3.3.1.1.2 Prothrombin (FII) 
Heterozygosity for the 20210A allele of the common FII polymorphism 20210G/A in the 
untranslated 3 region of the Prothrombin (FII) gene (Poort et al, 1996) is found at a 
prevalence of 2.7% in the normal Caucasian population (n = 11.932, cumulative data from 
several studies). This mutant correlates with slightly elevated FII levels, suggesting a 
quantitative contribution to thrombophilia, and is found at a frequency of 7.1% in unselected 
patients with thombosis (n = 2884, cumulative data from several studies). The derived 
relative risk for thrombosis is 2.6. FII 20210A also seems to play a role in childhood stroke. 
Published data, however, do not give a clear picture.(Nowak - Gottl et al, 1999; Kenet et al, 
2000) At least, FII 201210A does not seem to be involved in re-infarction.(Kurnik et al, 2003).  
3.3.1.1.3 Factor V (FV) 
The FV mutation Arg506 to Gln506 (R506Q or FV Leiden) causes relative resistance against 
cleavage by the activated protein C (PC) complex.(Dahlbäck et al, 1993; Bertina et al, 1994) It 
has been identified as the most common significant genetic risk factor for thrombosis to 
date. The prevalence in the normal Caucasian population is on the average 5%, with 
prevalences in particular populations of up to 15%.(Zoller et al, 1996) The relative 
thrombotic risk for heterozygotes is 6- to 8-fold, whereas homozygotes carry an 80-fold 
relative risk. (Koster et al, 1993) In children with venous thrombosis, FV Leiden was 
identified in up to 30%(Aschka et al, 1996) In contrast to adults it may also play a role in 
childhood stroke. (Nowak - Gottl et al, 1999) 
3.3.1.1.4 Factor VIII (FVIII) 
Elevated FVIII seems to contribute to the risk of TE in children. Furthermore, persistence of 
elevated FVIII after TE may also predict an unfavorable prognosis (Goldenberg et al, 2004), 
see Laboratory parameters.  
3.3.1.1.5 Von Willebrand factor  
Due to its key position in platelet adhesion and aggregation under conditions of high shear 
forces, VWF plays a most important hemostatic role in arterial vessels and in the 
microcirculation.(Ruggeri, 2004) This suggests a significant contribution of VWF to arterial 
TE and to microangiopathies such as thrombotic thrombocytopenic purpura (TTP). An 
elevated level of VWF is an independent risk factor for myocardial infarction and stroke in 
adults.(Vischer, 2006) It has not yet been shown whether elevated VWF also plays a role in 
arterial thrombosis of childhood. In the neonate, supra large VWF multimers, which are the 
most active in primary hemostasis, are more abundant than later in life and correlate with a 
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very effective platelet dependent function of VWF in newborns.(Rehak et al, 2004) It can be 
speculated if these large multimers contribute to the higher rate of stroke in the perinatal 
period, but respective data have not been reported yet. However, it is now clear that supra 
large VWF multimers are responsible for the life-threatening condition of TTP (Lammle et al, 
2005).  
3.3.1.2 Inhibitors of hemostasis 
The hemostatic process is tightly regulated by specific inhibitors that act on coagulation 
factors and on the factors of primary hemostasis. Functionally most important are tissue 
factor pathway inhibitor, the PC system, antithrombin (AT) and the VWF cleaving protease 
ADAMTS13. Clinically, to date only the latter three are important. Involvement of the 
coagulation inhibitors AT, PC and Protein S (PS) is rare with a prevalence in unselected 
patients with thrombosis of 0.019 for AT, 0.037 for PC, and 0.023 for PS deficiency.(Pabinger 
& Schneider, 1996; Koster et al, 1995) Recently, severe deficiency of ADAMTS13 has been 
identified as the causative factor of the rare TTP in most TTP patients (Lammle et al, 2005).  
3.3.1.2.1 Protein C system 
The PC system comprises PC, PS and FV as co-factors. PC is activated to APC by thrombin, 
which changes its substrate specificity from FI to PC by being bound to thrombomodulin at 
the endothelial cell surface. APC cleaves and inactivates aFV and aFVIII at specific 
proteolytic sites, thereby regulating the formation of thrombin. Severe PC deficiency as well 
as severe PS deficiency correlates with purpura fulminans, a life-threatening 
thromboembolic disorder of the microcirculation and larger vessels. Heterozygous 
deficiency of either inhibitor correlates with venous TE. PC also binds plasminogen activator 
inhibitor 1 (PAI1) which then facilitates fibrinolysis. This dual function of PC suggests a 
central role in the regulation of thrombus formation.  
3.3.1.2.2 Antithrombin 
When bound to heparan sulfate on endothelial cells, AT inhibits thrombin but also aFXI, 
aFIX and aFX. Its action on thrombin is enhanced 1000-fold by heparin through an allosteric 
conformational change. In contrast, low-molecular-weight heparin makes AT more aFX 
specific. These effects are the basis for prophylactic or therapeutic anticoagulation by 
heparin. Even mild hereditary deficiency of AT function may correlate with thrombophilia 
with a penetrance higher than in PC and PS deficiency.  
3.3.1.2.3 ADAMTS13 
ADAMTS13 regulates the size of VWF multimers and thereby its functional activity in 
primary hemostasis. Its deficiency has clearly been assessed as playing the causative role in 
TTP.(Lammle et al, 2005) An acquired form, caused by autoantibodies against ADAMTS13, 
and an inherited form called Upshaw Schulman syndrome (USS) due to mutations in the 
gene, exist. Lack of the protease correlates with persistence of supra large VWF multimers 
and, on an adequate trigger (infection, stress, hypoxia), these large multimers will induce 
platelet adhesion and aggregation in the microcirculation with subsequent microangiopathy, 
finally resulting in organ failure and death in 80% of cases when untreated. Thrombosis of 
larger venous and arterial vessels has also been observed. In childhood, TTP is rare and 
seems more often inherited.(Schneppenhim et al, 2004) Oligo-symptomatic courses have 
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been observed, however, their long-term prognosis is not clear. In addition to the obvious 
causative role of severe ADAMTS13 deficiency in TTP, the impact of milder ADAMTS13 
deficiency as thrombophilic factor has not been assessed yet, but is subject of ongoing 
studies. ADAMTS13 has been identified as a potent antithrombotic in an animal model, 
(Chauhan et al, 2006) which may be of future therapeutic interest. 
3.3.1.3 Metabolic conditions 
3.3.1.3.1 MTHFR polymorphism 677C/T 
The rare condition of classical homocystinuria is most often caused by a deficiency of either 
cystathionine-ß-synthetase or 5-methyltetrahydrofolate-homocysteine-methyltransferase 
and correlates with frequent TE due to severe homocysteinemia causing endothelial cell 
damage. The activity of 5-methyl tetrahydrofolate-homocysteine-methyltransferase in turn 
depends on the availability of 5-methyl-tetrahydrofolate, regulated by 5, 10-methyl 
tetrahydrofolate-reductase (MTHFR). A common thermolabile MTHFR-variant (MTHFR, 
677C>T) correlates with a slightly elevated level of homocysteine. Although repeatedly 
claimed in many studies, this variant does not seem to be an independent risk factor for TE.  
3.3.1.3.2 Lipoprotein (a) 
Lipoprotein (a) is considered a significant venous and arterial risk factor for TE in 
children.(Nowak - Gottl et al, 1999; Nowak - Gottl et al, 1999) However, other reports could 
not confirm these findings.(Revel - Vilk et al, 2003) Levels of Lp(a), though genetically 
determined, vary considerably among different populations. Lp(a) has structural homology 
to plasminogen, suggesting a possible competitive mechanism of Lp(a) in fibrinolysis. 
However, the lack of correlation between severe plasminogen deficiency and TE speaks 
against this hypothesis.  
3.3.2 Acquired prothombotic risk factors 
3.3.2.1 Central venous catheters 
CVCs have become critically important as medical and supportive management of various 
diseases and have greatly improved quality of life. They bear two serious complications: 
thrombotic occlusion and CVC-associated DVT as well as systemic infections. CVCs seem to 
be the most important risk factor for DVT. The range of reported CVC-related DVT ranges 
from 1% to nearly 70%, reflecting the problem of different definitions, diagnostic methods 
and alertness.(Mitchell et al, 2003; Male et al, 2003) However, the estimated contribution of 
CVCs to all thromboembolic events in newborns is as high as 90% and over 50% in older 
children.(Parasuraman & Goldhaber, 2006) There are only a few controlled studies on the 
prevalence of CVC-related DVT and infection rate as well as the efficacy of antithrombotic 
measures to prevent catheter occlusion and infection.  
3.3.2.2 Childhood cancer 
TE is a well known complication in adult patients with cancer. With the exception of acute 
lymphoblastic leukemia (ALL), the knowledge about TE in childhood cancer is still limited. 
ALL has the highest rate of TE in childhood that is not necessarily related to the use of a 
CVC. In contrast, brain tumors have a rather low incidence of thrombosis with or without 
CVC.(Tabori et al, 2006) An overall estimation looks at a risk of up to 16%.  
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TE in cancer is the result of complex interactions of a variety of factors such as the 
malignancy itself, chemotherapy and its side effects including infections or dehydration, 
CVCs, the unbalanced hemostatic system with predominant hypercoagulability as well as 
possible hereditary thrombophilia. The impact of the different types of childhood 
malignancy on the hemostatic system is still not well understood. Most reports are 
regarding ALL and show the highest risk for TE under ALL/non-Hodgkin lymphoma 
(NHL) treatment is during induction and re-induction therapy that contains L-asparaginase, 
the most common site being the upper deep venous system and the cerebral veins.  
3.3.2.3 Thrombosis and antiphospholipid syndrome (APS) 
APS is an antibody-mediated thrombophilic state characterized by specific clinical 
manifestations of venous, arterial or small vessel TE at any site as well as the presence of 
antiphospholipid antibodies (APA) in the blood. In addition to DVT, acute ischemic stroke 
or transient ischemic attack are characteristic. APS is often associated with a number of 
autoimmune disorders.(Miyakis et al, 2006) APS in women causes adverse pregnancy 
outcome including unexplained still birth or prematurity because of severe placental 
insufficiency (multiple infarction) or severe (pre)eclampsia. APS is classified as primary and 
secondary; the clinical picture, however, is the same. Patients with no underlying disease are 
diagnosed as primary APS. Secondary APS refers to patients with underlying autoimmune 
(mainly rheumatologic) disorders as well as viral and bacterial infections or cancer.  
All proposed pathophysiological mechanisms share the binding of the APA to anionic 
protein-phospholipid-complexes, leading to activation of endothelial cells, platelets and 
prothrombin, interference with natural inhibitory pathways and fibrinolysis, and disruption 
of the binding of annexin V to phospholipids coating the vascular system.(Levine et al, 2002; 
Rand, 2003) There are clinical/laboratory diagnostic and therapeutic criteria for adults 
(Miyakis et al, 2006) that do not apply equally for children. There have been recent reports 
on gene expression profiles to identify subtle distinctions in order to define the clinical 
relevance of different APA.(Ortel, 2006; Ortel, 2006) Apart from DVT as the most frequent 
clinical symptom in children along with the presence of LAC and high risk of recurrence 
without adequate long-term anticoagulation, there is a subgroup of children presenting with 
perinatal stroke and no risk of recurrence independent of secondary antithrombotic 
prophylaxis.(Kenet, 2006)This underlines the discordance to adults and the need for 
diagnostic and therapeutic guidelines to be defined for pediatric patients.  
APA along with decreased activity of various coagulation factors, mainly F XII, are found in 
about 50% of otherwise healthy children with multiple viral infections, screened for 
prolonged a PTT preceding tonsillectomy or adenotomy.42,44 APA in this context are in 
association to the repeated infections and do not appear to be clinically relevant, carry no 
risk for bleeding or TE, and hence do not influence perioperative management. They usually 
disappear after tonsillectomy and/or with decreasing frequency of infectious episodes. In 
contrast, life-threatening TE including purpura fulminans may occur with varicella, which 
have been shown to have a increased prevalence of APA and associated PS 
deficiency.(Manco - Johnson, 1998) Bleeding is rare and responds to corticosteroids.  
3.3.2.4 Heparin – induced thrombocytopenia type 2 (HIT) 
The overall incidence of HIT type 2 is estimated around 1% of patients hospitalized in 
pediatric intensive care units.(Klenner et al, 2004; Newall et a, 2003) Most often it is observed 
in neonates and infants after cardiac surgery and in adolescents treated with unfractionated 
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heparin (UFH) for venous thrombosis. HIT-associated TE is mainly venous but arterial 
events may occur.  
3.3.2.5 Other acquired prothrombotic conditions 
Perinatal asphyxia, systemic infections/sepsis/DIC, congenital heart disease (CHD) and 
hypovolemia are the main risk factors in neonates, the latter particularly prone to arterial 
events in association with CHD and/or arterial catheters frequently used in an intensive care 
setting.47 There are additional factors in older children: trauma, major surgery, 
immobilization, estrogen containing contraceptives in adolescent girls, corticosteroid 
therapy, nephrotic syndrome, hemolytic uremic syndrome, inflammatory bowel disease, 
and rheumatic and other chronic disorders. To date, it remains an individual decision if and 
which antithrombotic prophylaxis should be offered considering additional and individual 
risk factors.  
3.4 Therapy and prophylaxis  
Irrespective of an underlying disease, every thromboembolic manifestation should be 
treated, aiming at the complete recanalization of the occluded vessel and stopping the 
thrombotic process. In the vast majority of cases thrombosis will resolve under heparin 
given for 5–14 days. Other therapy options with a higher risk such as thrombolytic therapy 
or surgical embolectomy should be limited for patients with extensive thrombosis and/or 
threatened organ function. As LMWH show considerable advantages over UFH for 
therapeutic as well as prophylactic purposes, the following recommendations are in favor of 
LMWH. Yet evidence shows no difference in the antithrombotic efficacy. For detailed 
recommendations refer to Table 4 and reference (Monagle et al, 2004). 
 
UFH i.v. Neonates < 5kg Children > 5kg Target aPTT at 4h 
loading dose 1 x 75 U/kg/10 min 1 x 75 U/kg/10 min
maintenance 25–30 U/kg/h 20 U/kg/h 60–85 sec. 
LMWH s.c. Neonates < 5kg Children > 5kg Target anti-FXa at 4 h 
initial treatment dose
Enoxaparin* 1 x 2.0 mg/kg/d 1 x 1.5 mg/kg/d 0.4–0.8 U/mL 
Dalteparin 1 x 200 U/kg/d 1 x 150 U/kg/d 0.4–0.8 U/mL 
Reviparin 2 x 150 U/kg/d 2 x 100 U/kg/d 0.5–1.0 U/mL 
initial prophylactic dose
Enoxaparin* 1 x 1.5 mg/kg/d 1 x 1.0 mg/kg/d < 0.4 U/mL 
Dalteparin 1 x 100 U/kg/d 1 x 50 U/kg/d < 0.4 U/mL 
Reviparin 2 x 50 U/kg/d 2 x 30 U/kg/d < 0.5 U/mL 
* 1 mg Enoxaparin = 110 anti-FXa units 
For UFH: aPTT 4 hours after loading dose and 4 hours after each dosage adjustment, at least once daily; 
keep AT level within normal range; daily blood count (platelets!). For LMWH: anti-FX activity 4 hours 
after injection 
Table 4. Recommended dosing of UFH and LMWH in neonates and children. 
Recommendations 
In children with VTE (CVL and non-CVL related): first TE for children: 
In children with thrombosis, we recommend anticoagulant therapy with either UFH or 
LMWH (Grade 1B). 
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Remark: Dosing of IV UFH should prolong the aPTT to a range that corresponds to an anti-
FXa level of 0.35 to 0.7 U/mL, whereas LMWH should achieve an anti-FXa level of 0.5 to 1.0 
U/mL 4 h after an injection for twice-daily dosing. 
We recommend initial treatment with UFH or LMWH for at least 5 to 10 days (Grade 1B). For 
patients in whom clinicians will subsequently prescribe VKAs, we recommend beginning oral 
therapy as early as day 1 and discontinuing UFH/LMWH on day 6 or later than day 6 if the 
INR has not exceeded 2.0 (Grade 1B). After the initial 5- to 10-day treatment period, we 
suggest LMWH rather than VKA therapy if therapeutic levels are difficult to maintain on VKA 
therapy or if VKA therapy is challenging for the child and family (Grade 2C). 
We suggest children with idiopathic TE receive anticoagulant therapy for at least 6 months, 
using VKAs to achieve a target INR of (INR range, 2.0 to 3.0) or alternatively usingLMWH 
to maintain an anti-FXa level of 0.5 to 1.0 U/mL (Grade 2C). 
Recurrent Idiopathic TE for Children 
Recommendations 
For children with recurrent idiopathic thrombosis, we recommend indefinite treatment with 
VKAs to achieve a target INR of 2.5 (INR range, 2.0 –3.0) [Grade 1A]. 
Remark: For some patients, long-term LMWH may be preferable; however, there are little or 
no data about the safety of long-term LMWH in children. 
Recurrent Secondary TE for Children 
Recommendations 
For children with recurrent secondary TE with an existing reversible risk factor for 
thrombosis, we suggest anticoagulation until the removal of the precipitating factor but for a 
minimum of 3 months (Grade 2C). In addition, with specific respect to the managementof 
CVL-related thrombosis: 1.2.8. If a CVL is no longer required, or is nonfunctioning, we 
recommend it be removed (Grade 1B). We suggest at least 3 to 5 days of anticoagulation 
therapy prior to its removal (Grade 2C). If CVL access is required and the CVL is still 
functioning, we suggest that the CVL remain in situ and the patient be anticoagulated 
(Grade 2C). 
For children with a first CVL-related DVT, we suggest initial management as for secondary 
TE as previously described. We suggest, after the initial 3 months of therapy, that 
prophylactic doses of VKAs (INR range, 1.5–1.9) or LMWH (anti-FXa level range, 0.1 to 0.3) 
be given until the CVL is removed (Grade 2C). If recurrent thrombosis occurs while the 
patient is receiving prophylactic therapy, we suggest continuing therapeutic doses until the 
CVL is removed but at least for a minimum of 3 months (Grade 2C). 
Use of Thrombolysis in Pediatric Patients With DVT. 
Recommendations 
In children with DVT, we suggest that thrombolysis therapy not be used routinely (Grade 
2C). If thrombolysis is used, in the presence of physiologic or pathologic deficiencies of 
plasminogen, we suggest supplementation with plasminogen (Grade 2C). 
Thrombectomy and IVC Filter Use in Pediatric Patients With DVT. 
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Recommendations 
If life-threatening VTE is present, we suggest thrombectomy (Grade 2C). 
We suggest, following thrombectomy, anticoagulant therapy be initiated to prevent 
thrombus reaccumulation (Grade 2C). 
In children _ 10 kg body weight with lower-extremity DVT and a contraindication to 
anticoagulation, we suggest placement of a temporary IVC filter (Grade 2C). 
We suggest temporary IVC filters should be removed as soon as possible if thrombosis is not 
present in the basket of the filter and when the risk of anticoagulation decreases (Grade 2C). 
In children who receive an IVC filter, we recommend appropriate anticoagulation for DVT 
(see 1.2) as soon as the contraindication to anticoagulation is resolved (Grade 1B). 
Pediatric Cancer Patients With DVT 
Use of Anticoagulants as Therapeutic Agents 
Recommendations 
In children with cancer, we suggest management of VTE follow the general 
recommendations for management of DVT in children. 
We suggest the use of LMWH in the treatment of VTE for a minimum of 3 months until the 
precipitating factor has resolved (eg, use of asparaginase) [Grade 2C]. 
Remark: The presence of cancer, and the need for surgery, chemotherapy or other 
treatments may modify the risk/benefit ratio for treatment of DVT, and clinicians should 
consider these factors on an individual basis. 
Use of Anticoagulant as Thromboprophylaxis 
Recommendations 
We suggest clinicians not use primary antithrombotic prophylaxis in children with cancer 
and central VADs (Grade 2C). 
3.4.1 Commonly used anticoagulants 
3.4.1.1 Unfractionated heparin 
The following disadvantages should be considered: the need for venous access for therapy 
and monitoring, age-dependent unpredictable pharmacokinetics; normal AT levels required; 
monitoring by a PTT prone to pre-analytic errors; risk for bleeding; risk for HIT. Intravenous 
UFH should only be given in the initial phase of antithrombotic therapy and then switched 
to LMWH.  
3.4.1.2 Low - molecular - weight heparin 
Advantages are easy subcutaneous administration once daily without need of venous 
access, predictable pharmacokinetics, minimal monitoring, minimized bleeding 
complications, reduced risk of HIT. Infants < 5 kg required about 50% higher doses than 
older children to reach equivalent anti-FXa levels.(Sutor et al, 2004) As a general guideline 
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we recommend LMWH with therapeutic anti-Xa levels for 4–6 weeks, followed by 
prophylactic dosage up to 6 months. For the treatment duration of different sites, types 
and age groups refer to references (Monagle et al, 2004; Andrew et al, 2000).  
3.4.1.3 Thrombolytic agents 
The agent of choice is rt-PA. Streptokinase should not be used because of its allergic 
reactions. The use of urokinase at least in the USA is restricted for safety concerns. rt-PA 
may be indicated if thrombosis is extensive or organ/life threatening. The established 
contraindications in adults apply for children as well but should be considered relative.53 
Therapeutic recommendations are listed in Table 5. 
 
Contraindications 
Strong within 10 days after hemorrhage or major surgery
 within 7 days after severe asphyxia
 within 3 days after invasive procedure
Soft within 48 hours after cerebral convulsion
 prematurity < 32 weeks of gestation
 sepsis
 active minor hemorrhage
 refractory thrombcytopenia and hypofibrinogenemia
Therapy Loading Dose Maintenance Monitoring 
rt-PA 0.1–0.2 mg/kg/10 min. 0.8–2.4 mg/kg/24 h FI, platelets, D-dimers 
UFH none 5–10 U/kg/h Apt
Indications: extensive and/or life/organ-threatening thrombosis. Contraindications: on an individual 
basis to be considered relative, not absolute; keep fibrinogen > 0.5 g/L and platelets > 50 g/L; 
increasing D-dimers indicate effective fibrinolysis; dose reduction or cessation of rt-PA if major 
bleeding occurs; minor bleeding (oozing from catheter puncture site or wound) treat with local 
pressure; optimal duration of rt-PA therapy uncertain, mostly up to 7 days, shorter/longer courses 
Table 5. Recommendations for systemic thrombolysis in neonates and children 
3.4.1.4 Vitamin K antagonists 
 
OAC Day 1 Day 2 From Day 3 Target INR 
Phenprocoumon 6 mg/m2 3 mg/m2 1–2 mg/m2 2.0–3.0 
Warfarin 0.2 mg/kg 0.2 mg/kg 0.1–0.3 mg/kg 2.0–3.0 
Reversal of oral anticoagulant therapy 
no bleeding, slow reversal vitamin K 0.5–2.0 (–5.0) mg orally (s.c., i.v.) 
no bleeding, rapid 
reversal 
vitamin K 0.5–2.0 (–5.0) mg s.c. or i.v. 
significant bleeding, not 
life threatening 
vitamin K 0.5–2.0 (–5.0) mg s.c. or i.v. + FFP 20 mL/kg 
significant bleeding, life 
threatening 
vitamin K 5 mg i.v. over 20 min. (risk of anaphylactic shock) + 
prothrombin concentrate (Prothomplex) 50 U/kg i.v. 
Coumarin therapy always to begin with concomitant heparin therapy (UFH or LMWH); to stop 
heparin, INR within therapeutic range for 2 days, concomitant medication at least 5 days; attention to 
multiple drug interactions 
Table 6. Recommended dosing of oral anticoagulants (OAC) in neonates and children. 
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Warfarin and phenprocoumon are usually administered for oral anticoagulation and inhibit 
g-carboxylation of vitamin K–dependent proteins. Considerable variation due to nutrition, 
co-medication, intercurrent illness and difficult monitoring requires close supervision and 
dose adjustment. We administer vitamin K antagonists in cases of prophylaxis exceeding 6 
months (Table 6). 
3.4.1.5 Infusion of deficient inhibitors of hemostasis 
In cases of thrombosis with hereditary or acquired deficiencies of coagulation inhibitors, 
replacement therapy may be an option. Concentrates of AT and PC are commercially 
available and are life saving in conditions of purpura fulminans due to inhibitor deficiency. 
PC concentrate also proved to be effective in heterozygous or acquired PC deficiency. Fresh 
frozen plasma is the only but effective option of treating patients with purpura fulminans or 
hereditary TTP due to PS or ADAMTS13 deficiency, respectively.  
3.4.2 New anticoagulants 
The limitations of the traditional anticoagulants are particularly obvious in pediatrics; hence, 
the promotion of the new drugs already approved in adults urgent. Yet there is but 
individual experience in children with the following substances: the pentasaccharides 
fondaparinux and idraparinux, and the direct thrombin inhibitors hirudin, bivalirudin, 
argatroban; ximelagatran has been withdrawn from the market because of hepatic 
toxicity.(Balsa, 2005; Kuhle et al, 2006).  
3.4.3 Special conditions 
3.4.3.1 Prophylaxis of CVC occlusion 
3.4.3.1.1 UFH 
Prophylactic UFH seems to significantly decrease CVC-related DVT as well as bacterial 
colonization of the catheter.(Hentschen & Sutor, 2002) Heparin-bonded catheters do not 
reduce clot formation and bacterial colonization beyond 24 hours after CVC insertion.  
3.4.3.1.2 Thrombolytic agents (urokinase, rt - PA) 
Thrombolytic therapy is widely and safely used for the management of occluded catheters. 
There are only a few studies using thrombolytic agents prophylactically in order to reduce 
catheter infections and occlusions. Some studies show a substantial benefit of thrombolytic 
agents over UFH or no prophylaxis.(Hentschen & Sutor, 2002) whereas others get 
contradictory results.(Aquino et al, 2002; Solomon et al, 2000)  
3.4.3.1.3 LMWH 
Prophylactic use of LMWH has been efficient and safe in the treatment and prevention of 
DVT in children with cancer.(Elhasid et al, 2001; Massicotte et al, 2003; Tabori et al, 2006) 
However, LMWH to maintain CVC-patency and prevent CVC-related DVT has to remain an 
individual decision. For the recommended dosage see Table 4.  
3.4.3.1.4 Oral anticoagulation with vitamin K - antagomist 
There are no data for children on using low-dose oral anticoagulation to prevent CVC-
associated DVT and to maintain catheter patency. Considering the heterogeneous pediatric 
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population requiring a CVC with respect to age, thrombogenic risk profile, underlying 
disease, intensity and duration of treatment, the use of vitamin K–antagonists must remain a 
decision on a strictly individual base.  
3.4.3.2 Management of Thrombosis in children with cancer 
The main challenge is to keep the balance of benefit and risk of an antithrombotic treatment, 
as most children are being treated with chemotherapy with intermittent thrombocytopenia 
and an unbalanced hemostatic system, both of which lead to potential bleeding 
complications. It is therefore strongly recommended not to use antithrombotic agents with 
potentially serious side effects such as thrombolytic agents, UFH or vitamin K antagonists.  
Recommendations 
In children with cancer, we suggest management of VTE follow the general 
recommendations for management of DVT in children. 
We suggest the use of LMWH in the treatment of VTE for a minimum of 3 months until the 
precipitating factor has resolved (eg, use of asparaginase) [Grade 2C]. 
Remark: The presence of cancer, and the need for surgery, chemotherapy or other 
treatments may modify the risk/benefit ratio for treatment of DVT, and clinicians should 
consider these factors on an individual basis. 
3.4.3.3 Prophylaxis of TE in children with cancer 
Since a high percentage of TE seems to be directly CVC-related, it is of primary importance 
to maintain its patency. Though there is a lack of clear evidence based indications the 
following situations for primary prophylaxis may be individually considered: 1) children 
with hereditary thrombophilia under intensive chemotherapy, 2) adolescents in the presence 
of additional risk factors such as major surgery or immobilization, 3) patients with prior TE 
in their history and 4) children with tumors compressing large vessels. Because ALL carries 
the highest risk for TE an efficient prophylaxis would be of major importance. To date there 
are no controlled trials that allow the extrapolation of prophylactic strategies. The German 
BFM-Study Group is conducting the first randomized interventional trial comparing three 
different antithrombotic strategies during ALL-induction therapy (Thrombotect). This 
ongoing trial is expected to provide the basis for risk adapted prophylaxis guidelines.  
3.4.3.4 Antithrombotic therapy for APS 
Long-term prognosis depends on the risk of recurrent TE, which seems to be the highest 
within 6 months of discontinuation of anticoagulation.64 Duration and intensity of therapy 
are still controversial, at least for subgroups. After the first DVT, secondary prophylaxis for 
12 months is indicated. Lifelong anticoagulation is to be considered after a very serious first 
event and recurrent TE with persistence of APA. After arterial TE the optimal secondary 
prophylaxis remains controversial.64,65 In children consideration should be given to 
performing and/or extending first/second line antithrombotic treatment on an individual 
basis, depending on the presence of underlying disorders.  
Recommendations 
For children with VTE, in the setting of APLA (Antiphospholipid Antibodies), we suggest 
management as per general recommendations for VTE management in children. 
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Remark: Depending on the age of the patient, it may be more appropriate to follow adult 
guidelines for management of VTE in the setting of APLA. 
3.4.3.5 Treatment - related indications for Thrombophilia Screening 
It makes a difference if children are diagnosed and treated as study patients or if they are 
individually seen. In the latter case, laboratory work-up of thrombosis in childhood should 
pertain to the following basic questions: i) is there a specific therapy and ii) what are the 
consequences of a particular finding concerning future management and counseling of the 
patient and the family? (Sutor, 2003) Keeping this in mind, the necessary investigations are 
only a few (see Table 7) which is at odds with the current recommendations published by 
the Subcommittee on Perinatal/Pediatric Hemostasis of the Scientific and Standardization 
Committee (SSC) of the International Society on Thrombosis and Hemostasis (ISTH). 
(Manco - Johnson et al, 2002) However, since there is no consensus on management 
guidelines yet, laboratory testing may also vary between different institutions. It is well 
accepted that the coagulation inhibitors AT, PC and PS should be part of the diagnostic 
program. Though rare, their deficiencies can be compensated for by commercially available 
concentrates (AT, PC) and by fresh frozen plasma (PS). In cases of TE accompanied by 
hemolytic anemia and thrombocytopenia, Upshaw Schulman syndrome should be 
suspected and ADAMTS13 activity should be determined, since fresh-frozen plasma (FFP) is 
a life-saving replacement therapy in this condition and plasma exchange is the method of 
choice in the acquired form. Fasting homocysteine may be determined, since its elevation 
can be treated by folic acid substitution. However, two recent studies on lowering 
homocysteine by folate administration in patients with vascular disease did not show a 
reduction of re-infarction or stroke in adults.(Lonn et al, 2006; Ho et al, 2006) HIT type 2 
should be ruled out in patients with thrombosis who show a drop of the platelet count 
under heparin administration. APA should be determined, since the respective patients 
require a longer lasting prophylaxis against a relapse. There is no specific treatment for 
patients with Factor V Leiden or PT G20210A. Although these established hereditary risk 
factors are the most common, therapeutic and prophylactic measures are not necessarily 
different for children with or without these risk factors. Indeed, many studies on adults and 
a few on children have shown that these factors have only minor or even no impact on re-TE 
in unselected patients with or without these risk factors.(Kurnik et al, 2003; Ho et al, 2006) 
  
1 2 3 
Antithrombin APC resistance (FV Leiden) PAI-1 polymorphism 
Protein C Prothrombin G20210A Plasminogen 
Protein S Lipoprotein (a) Heparin-cofactor II 
Antiphospholipid-Ab Dysfibrinogenemia FIX 
Homocysteine FVIII FXI 
HIT Type 2 D-Dimer FXIII 
ADAMTS13  VWF 
Column 1: factors of therapeutic and/or prognostic relevance; column 2: established risk factors with 
possible therapeutic and prognostic relevance for the individual patient; column 3: potential 
thrombophilic factors. Their therapeutic and prognostic relevance for the individual patient is 
doubtful. Laboratory tests for HIT type 2 and ADAMTS13 are only indicated when additional data 
suggest their involvement (see text). 
Table 7. List of relevant, established and potential thrombophilic factors 
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As some studies have suggested, combined thrombophilic factors may enhance the risk of 
thrombosis. However, the risk of a second event in unselected patients does not seem to be 
high enough to justify more intense and prolonged anticoagulation, compared to patients 
without these risk factors. Deviations from this "minimalistic" diagnostic approach may be 
indicated with respect to the individual case and to the particular institutional management 
guidelines. Many other factors are part of diagnostic programs, although their contribution 
to the thrombotic risk seems to be very low or even absent. 
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